Nafamostat mesilate inhibits high-mobility group box 1 by lipopolysaccharide stimulation in murine macrophage RAW 264.7

Shock

Volumn 27, Issue 4, 2007, Pages 429-435

  Hagiwara, Satoshi ^a   Iwasaka, Hideo ^a   Matumoto, Sigekiyo ^a   Noguchi, Takayuki ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Anticoagulant; Cell signal; Late phage mediator; Lung injury; Sepsis

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; I KAPPA B; NAFAMSTAT MESILATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LINE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG INHIBITION; LUNG INJURY; LUNG PARENCHYMA; MACROPHAGE ACTIVATION; MALE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; RAT; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; THERAPY EFFECT; TREATMENT OUTCOME; UPREGULATION;

ANIMALS; CELL LINE; GUANIDINES; HMGB1 PROTEIN; LIPOPOLYSACCHARIDES; LUNG; MACROPHAGES; MALE; RATS; RATS, WISTAR; SERINE PROTEINASE INHIBITORS; TISSUE CULTURE TECHNIQUES;

EID: 34247170946     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000239778.25775.ad     Document Type: Article

References (32)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310, 2001.
2. Hudson LD, Milberg JA, Anardi D, Maunder RJ: Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 151:293-301, 1995.
3. Bustin M: Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 19:5237-5246, 1999.
4. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, Suffredini AF: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101:2652-2660, 2003.
5. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, Sohn JW, Yamada S, Maruyama I, Banerjee A, et al.: High mobility group box 1 protein (HMGB1) interacts with multiple Toll like receptors. Am J Physiol Cell Physiol 290:917-924, 2006.
6. Kokkola R, Andersson A, Mullins G, Ostberg T, Treutiger CJ, Arnold B, Nawroth P, Andersson U, Harris RA, Harris HE: RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 61:1-9, 2005.
7. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, et al.: HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-251, 1999.
8. Hatada T, Wada H, Nobori T, Okabayashi K, Maruyama K, Abe Y, Uemoto S, Yamada S, Maruyama I: Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 94:975-979, 2005.
9. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, Rauvala H, Herman G, Tracey KJ, Lee ML, Andersson J, Tokics L, Treutiger CJ: Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33:564-573, 2005.
10. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, et al.: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101:296-301, 2004.
11. Hitomi Y, Ikari N, Fujii S: Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 15:164-168, 1985.
12. Sugita H, Ishiko T, Ikei S, Hirota M, Ogawa M: FUT-175 inhibits the production of IL-6 and IL-8 in human monocytes. Res Commun Mol Pathol Pharmacol 103:57-64, 1999.
13. Noguchi S, Nakatsuka M, Konishi H, Kamada Y, Chekir C, Kudo T: Nafamostat mesilate suppresses NF-kappaB activation and NO overproduction in LPS-treated macrophages. Int Immunopharmacol 3:1335-1344, 2003.
14. Nakatsuka M, Asagiri K, Noguchi S, Habara T, Kudo T: Nafamostat mesilate, a serine protease inhibitor, suppresses lipopolysaccharide-induced nitric oxide synthesis and apoptosis in cultured human trophoblasts. Life Sci 67:1243-1250, 2000.
15. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K: Effect of nafamostat mesilate on pulmonary vascular injury induced by lipopolysaccharide in rats. Am J Respir Crit Care Med 155:711-718, 1997.
16. Murakami K, McGuire R, Cox RA, Jodoin JM, Bjertnaes LJ, Katahira J, Traber LD, Schmalstieg FC, Hawkins HK, Herndon DN, et al.: Heparin nebulization attenuates acute lung injury in sepsis following smoke inhalation in sheep. Shock 18:236-241, 2002.
17. Yang H, Wang H, Tracey KJ: HMG-1 rediscovered as a cytokine. Shock 15:247-253, 2001.
18. Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Tanaka M, Kobayashi A, Maruyama I, Yamada S, Hasegawa N, et al.: Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 170:1310-1316, 2004.
19. Lotze MT, Tracey KJ: High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331-334, 2005.
20. Mantell LL, Parrish WR, Ulloa L: HMGB-1 as a therapeutic target for infectious and inflammatory disorders. Shock 25:4-11, 2006.
21. Bhatia M, Moochhala S: Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. J Pathol 202:145-156, 2004.
22. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA: Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17:463-467, 2002.
23. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, Tracey KJ: Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126:389-392, 1999.
24. Adcock IM: Transcription factors as activators of gene transcription: AP-1 and NF-kappa B. Monaldi Arch Chest Dis 52:178-186, 1997.
25. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP, Arnold B, Bianchi ME, Manfredi AA, Rovere-Querini P: Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 174:7506-7515, 2005.
26. Lin WJ, Yeh WC: Implication of toll-like receptor and tumor necrosis factor alpha signaling in septic shock. Shock 24:206-209, 2005.
27. Guha M, Mackman N: LPS induction of gene expression in human monocytes. Cell Signal 13:85-94, 2001.
28. Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cheon HG: Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther 315:1188-1195, 2005.
29. Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr: Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 274:31868-31874, 1999.
30. Uchiba M, Okajima K, Kaun C, Binder BR, Wojta J: Gabexate mesilate, a synthetic anticoagulant, inhibits the expression of endothelial leukocyte adhesion molecules in vitro. Crit Care Med 31:1147-1153, 2003.
31. Yuksel M, Okajima K, Uchiba M, Okabe H: Gabexate mesilate, a synthetic protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kB and activator protein-1 in human monocytes. J Pharmacol Exp Ther 305:298-305, 2003.
32. Aosasa S, Ono S, Mochizuki H, Tsujimoto H, Ueno C, Matsumoto A: Mechanism of the inhibitory effect of protease inhibitor on tumor necrosis factor alpha production of monocytes. Shock 15:101-105, 2001.